Evidence map›Paper›PMID 38318174›Full record

Observational studyFrontiers in immunology2024

Brief research report: in-depth immunophenotyping reveals stability of CD19 CAR T-cells over time.

Ivan Odak, Lâle M Bayir, Lennart Riemann, Ruth Sikora, Jessica Schneider, Yankai Xiao, Nora Möhn, Thomas Skripuletz, Gernot Beutel, Matthias Eder and 4 more

Abstract readObservational Study
In one paragraph

Observational study in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ivan Odak *Institute of Immunology, Hannover Medical School, Hannover, Germany.
Lâle M Bayir *Institute of Immunology, Hannover Medical School, Hannover, Germany.
Lennart RiemannInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Ruth SikoraInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Jessica SchneiderInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Yankai XiaoInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Nora MöhnDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Thomas SkripuletzDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Gernot BeutelDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Matthias EderDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Arnold GanserDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Reinhold FörsterInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Christian R Schultze-Florey *Institute of Immunology, Hannover Medical School, Hannover, Germany.
Christian Koenecke *Institute of Immunology, Hannover Medical School, Hannover, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Variability or stability might have an impact on treatment success and toxicity of CD19 CAR T-cells. We conducted a prospective observational study of 12 patients treated with Tisagenlecleucel for CD19

Indexed as

Adaptor Proteins, Signal TransducingImmunophenotypingAntigens, CD19HumansProspective StudiesT-LymphocytesAdaptor Proteins, Signal TransducingAntigens, CD19ALL acute lymphoblastic leukemiaCAR T-cellCRS cytokine release syndromeDLBCL diffuse large B-cell lymphomaICANS immune effector cell associated neurotoxicity syndromeimmunophenotypingspectral flow cytometrytisagenlecleucel tisa-cel

Identifiers

PMID38318174
PMCPMC10839090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.